BRIEF published on 07/12/2025 at 00:05, 8 months 11 days ago BioNxt Solutions propose une offre d'unités d'obligations convertibles Placement Privé Développement De Produits Informations Pour Les Investisseurs Obligation Convertible Solutions BioNxt
BRIEF published on 07/12/2025 at 00:05, 8 months 11 days ago BioNxt Solutions Proposes Convertible Debenture Unit Offering Private Placement Convertible Debenture Investor Information Product Development BioNxt Solutions
PRESS RELEASE published on 07/12/2025 at 00:00, 8 months 11 days ago BioNxt Solutions Announces Convertible Debenture Unit Private Placement BioNxt Solutions Inc. announces $1.2M non-brokered private placement of convertible debenture units for product development and commercialization Private Placement Convertible Debentures BioNxt Solutions Inc. Commercialization Product Development
BRIEF published on 07/09/2025 at 03:32, 8 months 14 days ago BioNxt Solutions innove dans l'administration ciblée de médicaments de chimiothérapie Oncologie De Précision Solutions BioNxt Administration De Médicaments Innovations Pharmaceutiques Chimiothérapie Ciblée
BRIEF published on 07/09/2025 at 03:32, 8 months 14 days ago BioNxt Solutions Innovates Targeted Chemotherapy Drug Delivery Precision Oncology Drug Delivery BioNxt Solutions Pharmaceutical Innovations Targeted Chemotherapy
PRESS RELEASE published on 07/09/2025 at 03:27, 8 months 14 days ago BioNxt Solutions Introduces Targeted Chemotherapy Drug Delivery Platform for Precision Oncology BioNxt Solutions Inc. announces breakthrough targeted chemotherapy delivery platform for precision oncology, focusing on tumor-specific drug release and neutralization mechanism Precision Oncology BioNxt Solutions Inc. Drug Delivery Targeted Chemotherapy Chemotherapy Market
BRIEF published on 07/07/2025 at 09:10, 8 months 15 days ago BioNxt Advances Sublingual Cladribine Program for MS Pharmaceutical Development Multiple Sclerosis Treatment BioNxt Solutions Sublingual Cladribine Patient Compliance
BRIEF published on 07/07/2025 at 09:10, 8 months 15 days ago BioNxt fait progresser le programme de cladribine sublinguale pour la sclérose en plaques Développement Pharmaceutique Solutions BioNxt Cladribine Sublinguale Conformité Des Patients Traitement De La Sclérose En Plaques
PRESS RELEASE published on 07/07/2025 at 09:05, 8 months 15 days ago BioNxt's Sublingual Cladribine Program for MS Ready for Next Phase BioNxt Solutions receives cladribine API for BNT23001 sublingual thin-film formulation treating multiple sclerosis. Initiates clinical batch production with European partner Gen-Plus GmbH & Co KG Multiple Sclerosis BioNxt Solutions BNT23001 Cladribine API Sublingual Film
BRIEF published on 06/28/2025 at 01:55, 8 months 25 days ago BioNxt Solutions MCTO Revoked by British Columbia Securities Commission Cease Trade Order Annual Filings Trading Resumption Securities Commission BioNxt Solutions
Published on 03/23/2026 at 02:00, 1 hour 39 minutes ago FutureGen Industries Announces Open Market Investments
Published on 03/20/2026 at 13:30, 2 days 14 hours ago Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/22/2026 at 12:23, 15 hours 15 minutes ago Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 2 days 4 hours ago Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 2 days 6 hours ago Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 2 days 6 hours ago Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Published on 03/20/2026 at 19:00, 2 days 8 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 8 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 9 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 9 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
